Skip to Content

Medigene AG Namen-Akt. nach Kapitalherabsetzung MDGEF

Morningstar Rating
$1.55 −0.43 (21.64%)
View Full Chart
Unlock Our Analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

MDGEF is trading at a 52% discount.
Price
$1.56
Fair Value
$5.93
Uncertainty
Extreme
1-Star Price
$97.37
5-Star Price
$7.26
Economic Moat
Vbbf
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MDGEF is a good fit for your portfolio.

Trading Information

Previous Close Price
$1.98
Day Range
$1.551.56
52-Week Range
$1.552.35
Bid/Ask
$1.50 / $1.84
Market Cap
$38.07 Mil
Volume/Avg
12,510 / 5,302

Key Statistics

Price/Earnings (Normalized)
Price/Sales
4.03
Dividend Yield
Dividend Yield (Forward)
Total Yield

Company Profile

Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
87

Valuation

Metric
MDGEF
Price/Earnings (Normalized)
Price/Book Value
1.16
Price/Sales
4.03
Price/Cash Flow
Price/Earnings
MDGEF

Financial Strength

Metric
MDGEF
Quick Ratio
3.04
Current Ratio
4.74
Interest Coverage
−64.17
Quick Ratio
MDGEF

Profitability

Metric
MDGEF
Return on Assets (Normalized)
−50.94%
Return on Equity (Normalized)
−68.68%
Return on Invested Capital (Normalized)
−62.38%
Return on Assets
MDGEF

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRLfll$451.0 Bil
VRTX
Vertex Pharmaceuticals IncWpgdz$91.3 Bil
REGN
Regeneron Pharmaceuticals IncVhdkrzy$89.4 Bil
SGEN
Seagen Inc Ordinary SharesBbnrdv$40.7 Bil
MRNA
Moderna IncSrz$29.8 Bil
ARGX
argenx SE ADRDln$27.8 Bil
BNTX
BioNTech SE ADRHdjk$23.5 Bil
ALNY
Alnylam Pharmaceuticals IncHywvnkl$21.4 Bil
BMRN
Biomarin Pharmaceutical IncBthlhr$17.6 Bil
INCY
Incyte CorpFbymzz$12.3 Bil